FDA re­vis­es guid­ance on post­mar­ket­ing stud­ies to re­flect ARIA sys­tem, SUP­PORT act

The FDA on Thurs­day re­vised its draft guid­ance on post­mar­ket­ing stud­ies and clin­i­cal tri­als un­der Sec­tion 505(o)(3) of the Fed­er­al Food, Drug, and Cos­met­ic Act …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER